Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

NCT03872180 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03872180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03872180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 11, 2019
Completion date
July 15, 2027
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ccnd1 positive, mantle cell lymphoma, t(11;14) positive